Israel & Middle East · raised · Biotech / Healthcare
A 41-patient Parkinson's trial cut total MDS-UPDRS scores by 9.7 points against 1.95 points for controls on levodopa and a placebo app.
Remepy pairs prescription digital protocols with existing drugs to form hybrid treatments. A 41-patient Parkinson's Phase IIa trial cut total MDS-UPDRS scores by 9.7 points versus 1.95 for levodopa plus a placebo app. Merck KGaA's venture arm led its $36 million Series A.